Literature DB >> 19726873

CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans.

John D Campbell1, Yan Cho, Martyn L Foster, Holger Kanzler, Melissa A Kachura, Jeremy A Lum, Marianne J Ratcliffe, Atul Sathe, Andrew J Leishman, Ash Bahl, Mark McHale, Robert L Coffman, Edith M Hessel.   

Abstract

CpG-containing immunostimulatory DNA sequences (ISS), which signal through TLR9, are being developed as a therapy for allergic indications and have proven to be safe and well tolerated in humans when administrated via the pulmonary route. In contrast, ISS inhalation has unexplained toxicity in rodents, which express TLR9 in monocyte/macrophage lineage cells as well as in plasmacytoid DCs (pDCs) and B cells, the principal TLR9-expressing cells in humans. We therefore investigated the mechanisms underlying this rodent-specific toxicity and its implications for humans. Mice responded to intranasally administered 1018 ISS, a representative B class ISS, with strictly TLR9-dependent toxicity, including lung inflammation and weight loss, that was fully reversible and pDC and B cell independent. Knockout mouse experiments demonstrated that ISS-induced toxicity was critically dependent on TNF-alpha, with IFN-alpha required for TNF-alpha induction. In contrast, human PBMCs, human alveolar macrophages, and airway-derived cells from Ascaris suum-allergic cynomolgus monkeys did not produce appreciable TNF-alpha in vitro in response to ISS stimulation. Moreover, sputum of allergic humans exposed to inhaled ISS demonstrated induction of IFN-inducible genes but minimal TNF-alpha induction. These data demonstrate that ISS induce rodent-specific TNF-alpha-dependent toxicity that is absent in humans and reflective of differential TLR9 expression patterns in rodents versus humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19726873      PMCID: PMC2735936          DOI: 10.1172/JCI38294

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  CpG-containing oligodeoxynucleotides induce TNF-alpha and IL-6 production but not degranulation from murine bone marrow-derived mast cells.

Authors:  F G Zhu; J S Marshall
Journal:  J Leukoc Biol       Date:  2001-02       Impact factor: 4.962

3.  Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages.

Authors:  Matthew J Sweet; Carol C Campbell; David P Sester; Damo Xu; Rebecca C McDonald; Katryn J Stacey; David A Hume; Foo Y Liew
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

4.  Oligodeoxynucleotides containing CpG motifs induce low levels of TNF-alpha in human B lymphocytes: possible adjuvants for Th1 responses.

Authors:  B Bohle; L Orel; D Kraft; C Ebner
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

5.  Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.

Authors:  A Krug; A Towarowski; S Britsch; S Rothenfusser; V Hornung; R Bals; T Giese; H Engelmann; S Endres; A M Krieg; G Hartmann
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

6.  Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.

Authors:  T K Hart; R M Cook; P Zia-Amirhosseini; E Minthorn; T S Sellers; B E Maleeff; S Eustis; L W Schwartz; P Tsui; E R Appelbaum; E C Martin; P J Bugelski; D J Herzyk
Journal:  J Allergy Clin Immunol       Date:  2001-08       Impact factor: 10.793

7.  CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma.

Authors:  D Serebrisky; A A Teper; C K Huang; S Y Lee; T F Zhang; B H Schofield; M Kattan; H A Sampson; X M Li
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

8.  Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates.

Authors:  Chutitorn Ketloy; Anneke Engering; Utaiwan Srichairatanakul; Amporn Limsalakpetch; Kosol Yongvanitchit; Sathit Pichyangkul; Kiat Ruxrungtham
Journal:  Vet Immunol Immunopathol       Date:  2008-05-08       Impact factor: 2.046

9.  Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens.

Authors:  N Kadowaki; S Ho; S Antonenko; R W Malefyt; R A Kastelein; F Bazan; Y J Liu
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

10.  The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor.

Authors:  Michel Gilliet; Andre Boonstra; Carine Paturel; Svetlana Antonenko; Xiu-Ling Xu; Giorgio Trinchieri; Anne O'Garra; Yong-Jun Liu
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

View more
  29 in total

1.  Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity.

Authors:  Chasity D Andrews; Myung-Sook Huh; Kathryn Patton; Debbie Higgins; Gary Van Nest; Gary Ott; Kyung-Dall Lee
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

Review 2.  Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination.

Authors:  Christophe J Desmet; Ken J Ishii
Journal:  Nat Rev Immunol       Date:  2012-06-22       Impact factor: 53.106

Review 3.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system.

Authors:  Liang Cheng; Zheng Zhang; Guangming Li; Feng Li; Li Wang; Liguo Zhang; Sandra M Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  Vaccine       Date:  2017-09-25       Impact factor: 3.641

5.  The role of Bcl-xL in mouse RPE cell survival.

Authors:  Sarah Medearis; Ian C Han; Jessica K Huang; Ping Yang; Glenn J Jaffe
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-17       Impact factor: 4.799

Review 6.  Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.

Authors:  Jason R Baird; Arta M Monjazeb; Omid Shah; Heather McGee; William J Murphy; Marka R Crittenden; Michael J Gough
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-19       Impact factor: 7.038

7.  Targeting ST2L potentiates CpG-mediated therapeutic effects in a chronic fungal asthma model.

Authors:  Hemanth Ramaprakash; Takehiko Shibata; Karen E Duffy; Ugur B Ismailoglu; Rachel M Bredernitz; Ana Paula Moreira; Ana L Coelho; Anuk M Das; Natalie Fursov; Geoffrey L Chupp; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2011-05-14       Impact factor: 4.307

8.  Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.

Authors:  Jillian L Perry; Shaomin Tian; Nisitha Sengottuvel; Emily B Harrison; Balachandra K Gorentla; Chintan H Kapadia; Ning Cheng; J Christopher Luft; Jenny P-Y Ting; Joseph M DeSimone; Chad V Pecot
Journal:  ACS Nano       Date:  2020-06-02       Impact factor: 15.881

9.  Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand.

Authors:  Christina C N Wu; Brian Crain; Shiyin Yao; Mojgan Sabet; Fitzgerald S Lao; Rommel I Tawatao; Michael Chan; Donald F Smee; Justin G Julander; Howard B Cottam; Donald G Guiney; Maripat Corr; Dennis A Carson; Tomoko Hayashi
Journal:  J Innate Immun       Date:  2013-11-01       Impact factor: 7.349

10.  Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.

Authors:  Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Paul M Sondel; Alexander L Rakhmilevich
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.